Abbott Laboratories 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed on October 18, 2017, reports the results of operations for Abbott Laboratories for the third quarter of 2017. The filing incorporates by reference a press release (Exhibit 99.1) detailing these results.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of these metrics in the attached press release but does not list them within the 8-K body.
Material Changes and Non-GAAP Adjustments
Management utilizes non-GAAP financial measures to assess ongoing performance. The filing lists specific items excluded from these non-GAAP measures, which include:
- Expenses associated with acquisitions and restructuring actions.
- Charges related to cost reduction initiatives.
- Gains and deferred taxes from the sale of the Medical Optics business.
- Adjustments to the equity investment in Mylan.
- Venezuela devaluation losses.
- Tax benefits from the resolution of prior-year tax positions.
- Intangible amortization expense.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, outlook figures, or detailed risk factors. Management cautions investors that non-GAAP measures should be considered in addition to, not as a substitute for, GAAP financial measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2017 revenue and earnings figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings, specifically regarding the Medical Optics sale and Venezuela devaluation losses.
- Confirm the impact of intangible amortization on reported margins.
- Check for any updated full-year guidance provided in the referenced press release.